A Randomized, Open-label, Active-controlled, Parallel, Multicenter, Phase IV Clinical Study to Compare the Efficacy and Safety of Switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in Patients With Type 2 Diabetes
Latest Information Update: 22 May 2025
At a glance
- Drugs Dapagliflozin/pioglitazone (Primary) ; Metformin (Primary) ; Dapagliflozin/metformin/sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Boryung Pharmaceutical
Most Recent Events
- 22 May 2025 New trial record